Acidic pH Antifungal Activity of Ibrexafungerp Against Vaginal Candida

Study Background and Research Question

Vulvovaginal candidiasis (VVC) is a highly prevalent fungal infection, with up to 80% of women experiencing an episode during their lifetime and nearly half facing recurrent infections. The majority of VVC cases are caused by Candida albicans, but an increasing proportion is attributable to non-albicans Candida (NAC) species such as C. glabrata and C. krusei, many of which exhibit reduced susceptibility or resistance to azole antifungals. Compounding this challenge, the vaginal environment is distinctly acidic (pH 3.8–4.5), a factor known to reduce the efficacy of several antifungal agents, particularly azoles. Given rising azole resistance and the need for antifungals that retain potency at low pH, researchers evaluated whether ibrexafungerp, an oral non-competitive glucan synthase inhibitor in the triterpenoid class (also known as MK 3118), could fill this therapeutic gap.

Key Innovation from the Reference Study

The central innovation of the reference study is its direct assessment of ibrexafungerp’s in vitro activity against both fluconazole-susceptible and -resistant vaginal Candida isolates, using broth microdilution assays at both neutral (pH 7.0) and acidic (pH 4.5) conditions. Unlike previous antifungal studies, which often neglect the impact of acidic pH on drug efficacy, this work specifically addresses the clinical relevance of maintaining antifungal activity in the actual vaginal environment. The study’s findings provide strong evidence for ibrexafungerp’s stability and fungicidal activity in acidic conditions, setting it apart from traditional azoles whose efficacy is significantly diminished under similar circumstances.

Methods and Experimental Design Insights

The investigators collected 187 clinical vaginal isolates from women presenting with VVC, encompassing a diverse range of species: C. albicans (both fluconazole-sensitive and -resistant), C. glabrata, C. krusei, C. parapsilosis, and C. tropicalis. Isolates were identified via germ tube testing, CHROMagar plating, and fermentation profiling, ensuring species-level accuracy. All isolates were stored at –70°C and confirmed for purity before susceptibility testing.

Susceptibility testing followed the CLSI M27-A4 broth microdilution protocol, using RPMI 1640 as the medium and adjusting the pH to either 7.0 (neutral) or 4.5 (acidic) to simulate physiologic vaginal conditions. Ibrexafungerp minimum inhibitory concentrations (MICs) were determined after 24 hours of incubation at 35°C. Visual endpoints were defined as an 80% reduction in growth relative to the control. Quality control was ensured through parallel testing of standard ATCC strains.

Protocol Parameters

• Isolate selection: Clinical vaginal isolates; include both fluconazole-susceptible and -resistant strains.
• Species coverage: C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis.
• Susceptibility testing: Broth microdilution per CLSI M27-A4; perform assays at both pH 7.0 and pH 4.5.
• Inoculum density: 1.5 (±1.0) × 10³ cells/mL in RPMI 1640.
• Incubation: 35°C, 48 hours; MIC read at 24 hours (primary endpoint).
• Endpoint definition: Visual MIC; 80% reduction in turbidity compared to control.

Core Findings and Why They Matter

The study found that ibrexafungerp MIC values remained stable and potent against all vaginal Candida species tested, regardless of whether the assay was performed at pH 7.0 or pH 4.5. Specifically, the MIC₉₀ for both fluconazole-susceptible and -resistant C. albicans at pH 4.5 was 0.03 mg/mL, mirroring values observed at neutral pH. Similarly, strong efficacy was observed across C. glabrata, C. krusei, C. parapsilosis, and C. tropicalis. These results contrast with the marked reduction in fluconazole activity previously documented in acidic environments.

By retaining fungicidal activity at acidic pH, ibrexafungerp directly addresses a critical limitation of azole antifungals for VVC, offering a promising option for patients with azole-resistant infections or those with recurrent episodes, as described in the reference study. This property is particularly relevant in the context of increasing non-albicans Candida prevalence and rising azole resistance rates.

Comparison with Existing Internal Articles

The findings from this study are consistent with and extend previous research on ibrexafungerp’s efficacy in challenging clinical scenarios. For example, internal articles such as "Ibrexafungerp Efficacy Against Fluconazole-Resistant C. auris" and "Ibrexafungerp’s Efficacy Against Fluconazole-Resistant Candida auris" have highlighted the molecule’s robust activity against multidrug-resistant Candida species, including in delayed-treatment animal models. Similarly, studies on echinocandin-resistant Candida indicate that ibrexafungerp can overcome certain resistance mechanisms due to its distinct binding site on 1,3-β-D-glucan synthase. Most directly relevant, the internal article "Ibrexafungerp Activity in Acidic pH Against Vaginal Candida Isolates" supports the conclusion that ibrexafungerp’s antifungal potency is unaffected by acidic pH, further validating the present reference study’s methodology and findings.

Limitations and Transferability

While the study convincingly demonstrates stable in vitro activity of ibrexafungerp in acidic conditions, several limitations are noteworthy. First, as with all in vitro susceptibility studies, translation to in vivo efficacy requires confirmation, although preclinical animal models and early clinical trials have been encouraging. The study did not compare ibrexafungerp directly with other non-azole agents under identical acidic conditions, which could further contextualize its relative clinical utility. Additionally, the work focused on vaginal isolates; activity in other mucosal or systemic niches with different pH dynamics remains to be systematically explored. Finally, resistance development under selective pressure was not addressed and warrants longitudinal study.

Research Support Resources

For laboratories aiming to replicate or extend this work, ibrexafungerp (SKU C8697) is available as a research reagent from APExBIO, supporting workflows such as in vitro susceptibility testing (CLSI M27-A4), EUCAST 7.3.2 broth microdilution assays, and animal models of invasive or cutaneous candidiasis. Its physicochemical and storage properties, as detailed in the product information, align with the requirements for controlled antifungal screening. Researchers can leverage this tool to explore antifungal activity under various pH conditions, resistance phenotypes, and infection models relevant to clinical mycology.